• Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

    Source: Nasdaq GlobeNewswire / 04 Mar 2024 08:00:00   America/New_York

    SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Leerink Partners Global Biopharma Conference being held in Miami, FL, on March 11-13, 2024. The Company will host a fireside chat on Wednesday, March 13, 2024, at 10:00 am ET.

    A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.

    About Belite Bio
    Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on TwitterInstagramLinkedInFacebook, or visit us at www.belitebio.com.

    Media and Investor Relations Contact:
    Jennifer Wu
    ir@belitebio.com

    Julie Fallon
    belite@argotpartners.com


    Primary Logo

Share on,